Ovid Therapeutics (OVID) Free Cash Flow Growth (3y) (2019 - 2026)
Powered by 
Analysis
Ovid Therapeutics (OVID) Free Cash Flow Growth (3y) (2019 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 663.08 Bn | 642.33 Bn | 17.26 Bn | 33.62% |
| 2 | AbbVie | 453.04 Bn | 446.51 Bn | 12.70 Bn | -20.26% |
| 3 | Merck | 370.87 Bn | 363.78 Bn | 12.21 Bn | 17.80% |
| 4 | Novartis Ag | 305.29 Bn | 298.00 Bn | 11.24 Bn | 17.73% |
| 5 | Pfizer | 162.10 Bn | 150.70 Bn | 10.94 Bn | 28.91% |
| 6 | Sanofi | 53.95 Bn | 46.98 Bn | 10.79 Bn | 56.97% |
| 7 | Revolution Medicines | 45.00 Bn | 45.00 Bn | - | - |
| 8 | BeOne Medicines | 40.49 Bn | 35.39 Bn | 1.53 Bn | 45.09% |
| 9 | Incyte | 25.47 Bn | 20.94 Bn | 1.57 Bn | 18.29% |
| 10 | Ovid Therapeutics | 517.32 Mn | 400.10 Mn | - | -14.25% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -14.25% |
| Mar 31, 2026 | -4.66% |
| Dec 31, 2025 | -3.84% |
| Sep 30, 2025 | -0.46% |
| Jun 30, 2025 | 30.67% |
| Mar 31, 2025 | 20.07% |
| Dec 31, 2024 | 6.37% |
| Sep 30, 2024 | -11.31% |
| Jun 30, 2024 | 9.58% |
| Mar 31, 2024 | -28.14% |
| Dec 31, 2023 | 6.50% |
| Sep 30, 2023 | -88.85% |
| Jun 30, 2023 | 11.79% |
| Mar 31, 2023 | 13.29% |
| Dec 31, 2022 | 18.31% |
| Sep 30, 2022 | -10.10% |
| Jun 30, 2022 | -6.55% |
| Mar 31, 2022 | -16.08% |
| Dec 31, 2021 | -3.42% |
| Sep 30, 2021 | -2.31% |